Free Newsletter
Study revisits HRT heart attack risk
A new Danish study involving nearly 700,000 women showed that hormone replacement therapy might not put women at increased risk of heart disease, after all.
In 2002, the Women's Health Initiative study ended because of an increased risk of breast cancer, blood clots, stroke and heart attack in women taking a combination of estrogen and progestin. The study found an increased risk for breast cancer of nearly 25 percent for women taking either Premarin or Prempro.
Because of the announcement, many women discontinued the medications and sales of hormone replacement therapeutics dropped like a rock.
The researchers did not find any increased risk in older women taking the medication, but younger women, aged 51 to 54 years, had a risk of heart attack that was 24 percent higher than women who had never tried the therapy did. And women taking estrogen and progesterone together on a daily basis, as is the case with those taking Prempro, had a 35 percent greater risk.
However, this new study finds that taking the medication differently can lower the risk of heart attack, regardless of the type of estrogen or progesterone. Using a cyclic dosing strategy as well as applying the medication using a skin patch or a vaginal gel both lowered the risk of heart attack with HRT use.
Despite the new study findings, the authors still recommend taking the lowest dose of hormone replacement therapy for the least amount of time.
The study is published in the European Heart Journal.
- find the USA Today story
- read the ABC7.com news
Related Articles:
Wyeth wrestles with Prempro suits
Cancer risk lingers when hormones stop
FDA cries halt to 'bio-identical' hormones
HRT doesn't protect women from heart disease (Sept 2007)
Comments
It should be no surprise that the Women's Health Initiative (WHI) results continue to be defended even in the face of mounting evidence from around the world that the study was flawed. I wrote this same opinion over a year and a half ago to the Wall Street Journal, who chose not to respond because of the toxic nature of this topic. Why? Simply put, far too many physicians and researchers jumped on the bandwagon to oppose HRT for women and trumpet the dangers related to increased heart attack risk to cancer. Yet, as we continue to discover, these risks, if any, are minimal. Few bothered to explain how flawed the WHI was in the first place. Using synthetic hormones, measuring only individual hormone levels when any endocrinologist can tell you that both progesterone and estrogen should be supplemented, as only one will throw off the delicate balance of the "hormone net". Rather, the researchers were more apt to scream, "stop taking your premarin!" among other treatments and scare millions of women into abandoning their HRT which effectively treated myriad symptoms of their menopause and other indications. All to tout their brilliance, stewardship and vigilance on behalf of the consuming public. Poppycock to the WHI. Tell it like it is. A multi-year, multi-million dollar waste of taxpayer money in support of FDA and DEA desires to raise the ire of the population against hormones and support their own witch hunts of physicians and individuals who use HRT efficaciously and in support of their conditions. The message here is once again; "let the patient make the decision how effective or not a therapy is in concert with her physician and health care practitioner. Keep out of diagnosis and treatment at the patient level when therapies work with minimal side effects and don't create a panacea where none exists." No doubt we will hear many more reports of the failure of the WHI in the near future.
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





